Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

DSpace Repository

Show simple item record

dc.contributor.author Bedke, Jens
dc.date.accessioned 2021-12-20T09:30:40Z
dc.date.available 2021-12-20T09:30:40Z
dc.date.issued 2020
dc.identifier.issn 1474-5488
dc.identifier.uri http://hdl.handle.net/10900/121874
dc.language.iso en de_DE
dc.publisher Elsevier Science Inc de_DE
dc.relation.uri http://dx.doi.org/10.1016/S1470-2045(20)30436-8 de_DE
dc.subject.ddc 610 de_DE
dc.title Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial de_DE
dc.type Artikel de_DE
utue.quellen.id 20210304112512_00413
utue.publikation.seiten 1563-1573 de_DE
utue.personen.roh Powles, Thomas
utue.personen.roh Plimack, Elizabeth R.
utue.personen.roh Soulieres, Denis
utue.personen.roh Waddell, Tom
utue.personen.roh Stus, Viktor
utue.personen.roh Gafanov, Rustem
utue.personen.roh Nosov, Dmitry
utue.personen.roh Pouliot, Frederic
utue.personen.roh Melichar, Bohuslav
utue.personen.roh Vynnychenko, Ihor
utue.personen.roh Azevedo, Sergio J.
utue.personen.roh Borchiellini, Delphine
utue.personen.roh McDermott, Raymond S.
utue.personen.roh Bedke, Jens
utue.personen.roh Tamada, Satoshi
utue.personen.roh Yin, Lina
utue.personen.roh Chen, Mei
utue.personen.roh Molife, L. Rhoda
utue.personen.roh Atkins, Michael B.
utue.personen.roh Rini, Brian, I
dcterms.isPartOf.ZSTitelID Lancet Oncology de_DE
dcterms.isPartOf.ZS-Issue 12 de_DE
dcterms.isPartOf.ZS-Volume 21 de_DE
utue.fakultaet 04 Medizinische Fakultät de_DE


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record